Cayman and GenScript Partner to Offer Neoantigen Profiling and Synthesis Expertise

Ann Arbor, MI, August 15, 2020 --(PR.com)-- Cayman and GenScript have come together to create a complete package of neoantigen discovery services. Through combined efforts, MHC-associated peptides are identified and verified as immunogenic to guide peptide synthesis for vaccine development. “Cayman provides a complete workflow enabling the identification of peptide sequences as putative neoantigens. We are excited to add GenScript’s technical means and experience to synthesize peptides for our clients’ downstream applications and potential vaccine development,” said Dr. Michael Pisano, VP of Business Development and Contract Services at Cayman.

This service has wide applicability for neoantigen discovery projects, ranging from functional screening of candidates for T cell receptor therapy to clinical-stage peptide vaccine testing. “GenScript is excited to start this partnership with Cayman to provide a full immunopeptidome discovery and production service. By combining Cayman’s industry-leading expertise in immunopeptidome profiling with GenScript’s reliable service for difficult neoantigen peptide synthesis, we can offer a full-spectrum platform for the personalized immuno-oncology community,” said Dr. Samantha Zaroff, Product Manager of Neoantigen Peptides at GenScript.

By pooling resources, Cayman and GenScript have created a complementary partnership to deliver the highest quality and convenience to their customers.

About Cayman Chemical
Cayman Chemical Company helps make research possible by supplying scientists worldwide with biochemical tools used to understand cancer, neurochemistry, oxidative injury, endocrinology, atherosclerosis, and other human health challenges. Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others for use as research reagents and qualified standards. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination. In addition, Cayman Contract Services provides discovery and pre-clinical development services to the global pharmaceutical, biotechnology, and academic research markets. Our diverse suite of services leverages a team of over 150 highly skilled scientists with expertise in medicinal chemistry, structure-based drug design, complex multi-step organic synthesis, analytical chemistry, sample analysis, and custom assay development. Cayman performs generic drug development and production in both Ann Arbor, Michigan and Neratovice, Czech Republic.

About GenScript
GenScript Biotech Corporation is a global biotechnology group focused on leading gene synthesis technology. This includes operation as a Life Science CRO, enzyme and synthetic biology products, biologics development, and manufacturing, as well as cell therapy. Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics. GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.